

2026 EARLY AGE ONSET CANCER VIRTUAL SYMPOSIUM AGENDA EARLY AGE ONSET CANCER: REDEFINING CURRENT MODELS OF CANCER CARE IN CANADA November 19-20, 2026		
TARGET AUDIENCE: Oncology Professionals, Pathologists, Patients and Caregivers, Researchers, Advocates, Primary Care, Policy Professionals, Industry Goals: Education, Awareness, Advocacy		
Steering Committee: Dr. Michael Raphael (Co-Chair), Dr. Shady Ashamalla (Co-Chair), Dr. Perri Tutelman, Sarah Cleyn, Dr. Vincent Quoc-Huy Trinh, Dr. Chris Lieu, Peter Laneas		
DAY 1: NOVEMBER 19, 2026 RETHINKING EARLY AGE ONSET CANCER MANAGEMENT: ALIGNING SYSTEMS WITH A CHANGING PATIENT REALITY		
Time (ET)	Session Title & Description	Presenters/Speakers
9:30 a.m. – 9:45 a.m.	Symposium Day 1 Opening The Symposium will begin with opening remarks, an overview of the program, and a look at the key themes that will guide discussions over the next two days. The Colorectal Cancer Resource & Action Network (CCRAN) is a national, patient-focused advocacy group, dedicated to improving the longevity and quality of life for all cancer patients in Canada through their persistent efforts in support, education, and advocacy for equal and timely access to effective therapies. CCRAN's expanded mandate includes tumour types outside of the colorectal cancer space. CCRAN's sixth annual pan-tumour Early Age Onset Cancer (EAOC) Symposium builds on the foundation established by previous symposia. Over two days, clinicians, pathologists, researchers, patients, and caregivers from across Canada and beyond will come together to examine evolving	<u>Symposium Moderator:</u> Cassandra Macaulay, B.Sc., MHS, RTNM Chief Research Officer, CCRAN

	approaches to early age onset cancer care, advance optimal treatment and survivorship, and address the system-level challenges that continue to impact earlier diagnosis and equitable care.	
9:45 a.m. – 10:00 a.m.	Welcome from CCRAN’s President & CEO A welcome from CCRAN's President & CEO, followed by a conversation with a patient advocate reflecting on their lived experience with early age onset cancer. Together, they will explore the realities of navigating cancer as a younger adult and how lived experience is helping challenge and reshape current models of cancer care.	Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A. President & CEO, CCRAN <u>Patient Perspective</u> Corey Lasso Stage IV Colorectal Cancer Patient
10:00 a.m. – 10:30 a.m.	Key Learnings from CCRAN’s 2025 Early Age Onset Cancer Symposium The objectives and outcomes of CCRAN’s 2025 Early Age Onset Cancer Symposium have been captured and summarized in Current Oncology . The lead author of the publication will present the key findings, emerging themes, and proposed calls to action identified in the paper.	<u>Presentation</u> Dr. Michael Raphael, MD, FRCPC Medical Oncologist, Early Age Onset CRC Cancer Clinic Lead, Odette Cancer Centre, Sunnybrook Health Sciences Centre; Co-Chair, Medical & Scientific Advisory Board, CCRAN
10:30 a.m. – 11:15 a.m.	CCRAN Update: Advancing Change in Early Age Onset Cancer Care This presentation will highlight CCRAN's ongoing advocacy, research, education, and policy initiatives aimed at advancing early age onset cancer care across Canada. Updates will include progress in biomarker advocacy, colorectal cancer screening, Early Age Onset Cancer Awareness Day, and other strategic initiatives focused on improving timely, equitable, and patient-centred access to age-appropriate cancer care.	<u>Presentation</u> Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A. President & CEO, CCRAN
11:15 a.m. – 11:30 a.m.	Break	
11:30 a.m. – 1:00 p.m.	Colorectal Cancer Screening at 45: Implementation, Access, and System Readiness As rates of early age onset colorectal cancer continue to rise, screening policies across Canada are evolving in response to changing epidemiology and growing evidence supporting earlier detection. Following Prince Edward Island's decision in March 2026 to become the first province to lower the screening age for average-risk colorectal cancer, Ontario lowered the age of eligibility from 50 to 45 in July 2026 and introduced several updates to its ColonCancerCheck program , marking another important milestone in the evolution of colorectal cancer early detection.	<u>Moderator</u> TBD <u>Patient Perspective</u> TBD

	While policy change represents significant progress, its impact will depend on effective implementation, system readiness, public awareness, equitable participation, and sufficient capacity to meet increased demand. This session will examine the opportunities and challenges associated with translating screening policy into practice, while identifying strategies to strengthen early detection and improve outcomes for younger adults across Canada. Areas of discussion will include: • The evidence, policy developments, and system drivers shaping the evolution of colorectal cancer screening in Canada • Implementation considerations related to capacity, participation, equity, and healthcare system readiness as screening eligibility expands • Opportunities to strengthen early detection and maximize the long-term impact of colorectal cancer screening programs for younger adults	<u>Panelists</u> Dr. Shady Ashamalla, MD, MSc, FRCSC Surgical Oncologist, Odette Cancer Centre, Sunnybrook Health Sciences Centre; Head, Division of General Surgery, Sunnybrook Health Sciences Centre; Assistant Professor of Surgery, University of Toronto Dr. Erin McCarvill, MD, CCFP, FCFP Health PEI Medical Advisor for Cancer Prevention, Screening and Early Detection; GPO, PEI Cancer Treatment Centre Dr. Ioana Nicolau, Ph.D. Research Scientist, Cancer Epidemiology and Prevention Research (CEPR), Cancer Care Alberta; Adjunct Assistant Professor, Department of Oncology, Cumming School of Medicine, University of Calgary Dr. Robert Hilsden, MD, Ph.D., FRCPC Professor, Departments of Medicine and Community Health Sciences, University of Calgary; Gastroenterologist; Quality Improvement and Analytics Lead, Forzani & MacPhail Colon Cancer Screening Centre, Alberta Health Services Bronwen McCurdy, BSc, MPH Director, ColonCancerCheck/GI Endoscopy Program, Ontario Cervical Screening Program and Emerging Programs, Ontario Health (Cancer Care Ontario) <i>Additional panelists yet to be confirmed</i>
1:00 p.m. – 1:45 p.m.	Break Virtual Breakout Room (1:00 p.m. – 1:30 p.m.)	

1:45 p.m. – 2:45 p.m.	Training the Front-Line Primary Care Professionals: Embedding Early Age Onset Cancer Education Across Medical and Nursing Pathways As rates of early age onset cancer (EAOC) continue to rise, primary care providers are increasingly encountering cancers in populations historically considered low risk. Yet educational curricula, clinical training pathways, and professional development programs have not consistently evolved at the same pace as the changing epidemiology of cancer in younger adults. Delayed recognition can contribute to delays in diagnosis and missed opportunities for earlier intervention. This session will examine opportunities to strengthen medical and nursing education to better equip healthcare professionals with the knowledge and tools needed to recognize and appropriately investigate potential signs and symptoms of cancer in younger adults. Speakers will explore educational gaps, emerging initiatives, and strategies for integrating EAOC education across undergraduate, postgraduate, and continuing professional education to support earlier diagnosis and improve patient outcomes. Session focus: • Understand how evolving EAOC epidemiology is challenging traditional assumptions about cancer risk in younger populations • Explore educational and system-level approaches that support earlier recognition and investigation of potential cancer symptoms • Discuss opportunities to embed EAOC knowledge and best practices across healthcare training, professional development, and care delivery models	<u>Moderator</u> Sarah Cleyn RN, MN, CHPCN(C) Advanced Practice Nurse, Cancer Care Enhancements, The Ottawa Hospital Cancer Centre; AYA Program Lead, Champlain Regional Cancer Program <u>Patient Perspective</u> Alessandra De Angelis Stage II Colon Cancer Patient; Registered Dental Hygienist <u>Panelists</u> Trudy Matwiy, RN, MN, NP Master of Nursing/Nurse Practitioner, Family/All Ages; Nurse Practitioner Primary Care Program (NPPCP); Director of Primary Care, Nurse Practitioner Association of Alberta Dr. Amirrtha Srikanthan, MD, M.H.Sc., FRCPC, CHE Medical Lead, Adolescents and Young Adults (AYA) Cancer Program, Champlain Region; Associate Professor, Faculty of Medicine, University of Ottawa; Medical Oncologist, Division of Medical Oncology, Department of Medicine, The Ottawa Hospital Dr. Anna Wilkinson, MD, M.Sc., CCFP Family Physician; GP Oncologist; Associate Professor, Department of Family Medicine, University of Ottawa; Author <i>Additional panelists yet to be confirmed</i>
2:45 p.m. – 3:45 p.m.	Understanding Your Tumour’s Biology: Unlocking Personalized Treatment Opportunities No two cancers are the same. A deeper understanding of tumour biology is transforming cancer diagnosis and treatment, enabling more personalized care based on the unique molecular characteristics of an individual's tumour. Advances in biomarker testing, genomic profiling, and	<u>Moderator</u> Dr. Sharlene Gill, MD, MPH, MBA, FASCO Professor of Medicine, UBC; Medical Oncologist, BC Cancer - Vancouver; Medical & Scientific Advisory Board Co-Chair, Colorectal Cancer Resource & Action Network (CCRAN)

	precision oncology are helping identify targeted therapies, immunotherapies, clinical trial opportunities, and, in some cases, off-label treatment options. As precision oncology continues to evolve, understanding when advanced tumour testing may be appropriate and how these results can inform treatment decisions is becoming increasingly important. This session will explore how tumour profiling is improving treatment selection and expanding therapeutic opportunities for people affected by early age onset cancer. Experts will explore: • The role of tumour biology, biomarker testing, and genomic profiling in guiding personalized treatment decisions • How genomic testing can help identify targeted therapies, immunotherapies, clinical trial opportunities, and other emerging treatment options • Opportunities to incorporate comprehensive genomic profiling into routine clinical practice and support informed discussions between patients and healthcare teams	<u>Patient Perspective</u> TBD <u>Panelists</u> Dr. Lesleigh Abbott, MD, FRCPC Staff Physician, Pediatric Hematology/Oncology, The Children's Hospital of Eastern Ontario (CHEO); Associate Professor, University of Ottawa; Clinical Investigator, CHEO Research Institute Dr. Michael D. Carter, MD, Ph.D., FRCPC Medical Director, Molecular Diagnostics, Nova Scotia Health; Medical Director of Research, Division of Anatomical Pathology & Associate Professor of Pathology, Dalhousie University <i>Additional panelists yet to be confirmed</i>
3:45 p.m. – 4:00 p.m.	Break Featured Video: Second Look Cancer - Clinical Trial Matching Tool Dillan Eisenhaur, Founder	
4:00 p.m. – 5:00 p.m.	Artificial Intelligence in Oncology: Supporting Clinical Decision-Making Artificial intelligence (AI) is creating new opportunities to support clinical decision-making across cancer care. As oncology generates increasingly complex clinical, pathological, and molecular information, AI is emerging as a powerful tool to help clinicians interpret data, identify meaningful patterns, and support more personalized care. From tumour characterization and precision oncology to treatment planning, risk prediction, and clinical decision support, AI has the potential to enhance the quality and efficiency of oncology care. Realizing this potential, however, requires more than technological innovation. As AI moves from research into clinical practice, important questions remain regarding clinical utility, implementation, governance, and how these technologies can be responsibly integrated into routine cancer care. Discussion topics:	<u>Moderator</u> Dr. Jackie Bender Scientist and Co-Lead of Equity, Diversity and Inclusion, Department of Supportive Care, University Health Network; Associate Professor, Dalla Lana School of Public Health, University of Toronto <u>Patient Perspective</u> Dillan Eisenhaur Stage IV Colorectal Cancer Patient; Founder, Second Look Cancer

	• How AI is augmenting clinician decision-making while preserving clinical judgement and patient-centred care • The application of AI to support precision oncology, from molecular interpretation to personalized treatment planning • Bridging the gap between AI innovation and real-world clinical adoption	<u>Panelists</u> Dr. Rob Grant, MD, Ph.D., FRCPC Medical Oncologist, Princess Margaret Cancer Centre, University Health Network Dr. John-José Nuñez, MD, MSc, FRCPC Associate Medical Director, Supportive Care, BC Cancer Assistant Professor, Department of Psychiatry, University of British Columbia Dr. Muhammad Mamdani, PharmD, M.A., MPH Clinical Lead, Artificial Intelligence, Ontario Health; Director, Temerty Centre for Artificial Intelligence Research and Education in Medicine (T-CAIREM), University of Toronto; Professor, University of Toronto <i>Additional panelists yet to be confirmed</i>
5:00 p.m. – 5:15 p.m.	Glance at Day 2. Closing Remarks from CCRAN’s President & CEO.	Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A. President & CEO, CCRAN

2026 EARLY AGE ONSET CANCER VIRTUAL SYMPOSIUM AGENDA		
EARLY AGE ONSET CANCER: REDEFINING CURRENT MODELS OF CANCER CARE IN CANADA		
DAY 2: NOVEMBER 20, 2026		
ADVANCING CARE FOR EARLY AGE ONSET CANCER: INNOVATION, CARE PATHWAYS & THE PATIENT EXPERIENCE		
Time (ET)	Session Title & Description	Presenters/Speakers
9:30 a.m. – 9:45 a.m.	Symposium Day 2 Opening	<u>Symposium Moderator:</u> Cassandra Macaulay, B.Sc., MHS, RTNM Chief Research Officer, CCRAN

	A brief recap of key themes, insights, and discussions from Day 1, followed by an overview of the objectives and discussions that will shape Day 2 of the Symposium.	
9:45 a.m. – 10:00 a.m.	Welcome from CCRAN's President & CEO A welcome from CCRAN's President & CEO, followed by a conversation with a patient advocate reflecting on their lived experience with early age onset cancer. Together, they will explore the realities of navigating cancer as a younger adult and how lived experience is helping challenge and reshape current models of cancer care.	Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A. President & CEO, CCRAN <u>Patient Perspective</u> TBD <i>Additional speaker yet to be confirmed</i>
10:00 a.m. – 11:15 a.m.	When Care Doesn't Fit: Patient Perspectives on Navigating Cancer Within the Traditional Models of Care For many younger adults diagnosed with cancer, there remains a disconnect between the care they receive and the realities of living with cancer during one of the most formative stages of life. Beyond clinical decisions, patients are often navigating uncertainty, fragmented communication, psychosocial and emotional challenges, and complex healthcare systems while simultaneously managing careers, young families, financial responsibilities, social pressures, and evolving identities. This patient panel will examine the cancer journey through the lived experiences of younger adults, exploring where traditional models of care align with patient needs and where they do not. Rather than focusing solely on gaps in care, the discussion will consider what patients value most: the conversations that build trust, the supports that foster resilience, and the care experiences that help younger patients feel seen as individuals, not simply by their diagnosis. Together, these perspectives will challenge conventional approaches to care and identify opportunities to better meet the needs of younger adults diagnosed with cancer. Discussion themes will include: • The strengths and limitations of traditional models of care from the patient perspective • The care experiences, relationships, and psychosocial supports that had the greatest impact during treatment and survivorship, and the lessons they offer for future models of care • Patient-informed priorities for redesigning cancer care to better reflect the evolving needs and expectations of younger adults diagnosed with cancer	<u>Moderator</u> Peter Laneas Two-Time Testicular Cancer Survivor (Stage IIIA & IA); Advocate; Advocacy & Engagement Lead, Cancer Fatigue Services <u>Patient Panel</u> Sundas Shamshad Stage II HER2-Positive Breast Cancer Survivor; Founder, Sisters in Cancer YMM; Patient Advocate James Moriarty Stage IV Endometrial Cancer Survivor and Advocate Christopher Mammoliti, B.Comm. (Hons) Thyroid Cancer Survivor & Late-Stage Colon Cancer Survivor; Patient Advocate; Public School Board Trustee Candidate, Toronto Municipal Election Teri Price Caregiver to Late Brother Diagnosed with Testicular Cancer; Patient Safety Advocate & Executive Director, Greg's Wings Projects
11:15 a.m. – 11:30 a.m.	Break	

11:30 a.m. – 1:00 p.m.	Advancements in the Management of Pancreatic Cancer Pancreatic cancer remains one of the most complex and challenging malignancies to diagnose and treat. While historically associated with poor outcomes, recent advances in systemic therapies, biomarker-directed treatment, and precision medicine are beginning to reshape the management of pancreatic cancer. As therapeutic options continue to expand, clinicians are increasingly able to personalize treatment strategies and identify new opportunities through clinical research. This clinician roundtable will examine the latest advancements in the management of pancreatic cancer, highlighting evolving standards of care, emerging evidence, and innovative treatment approaches that are transforming clinical practice. Experts will discuss how these developments are improving outcomes, informing more individualized treatment decisions, and creating new opportunities for younger adults diagnosed with pancreatic cancer. Discussion topics: • Recent advances that are changing the management of pancreatic cancer • Integrating precision medicine into treatment planning and clinical decision-making • Opportunities to improve outcomes for younger adults through innovation, multidisciplinary care, and clinical research	<u>Moderator</u> Dr. Cathy Eng, MD, FACP, FASCO Vanderbilt-Ingram Cancer Center, Nashville, TN; David H. Johnson Chair in Surgical and Medical Oncology; Professor of Medicine, Hematology and Oncology; Director for Strategic Relations; Co-Director, GI Oncology; Co-Leader, Gastrointestinal Cancer Research Program; Director, Young Adult Cancers Program; Co-Chair, NCI Gastrointestinal Steering Committee <u>Patient Perspective</u> Jennifer Lovrics Caregiver to husband to succumbed to stage IV pancreatic cancer <u>Clinician Roundtable</u> Dr. Ravi Ramjeesingh, MD, Ph.D., FRCPC Medical Oncologist & Assistant Professor, Chair of the HPB Cancer Disease Site Group Halifax, Division of Medical Oncology and Department of Community Health and Epidemiology, Nova Scotia Cancer Centre & Dalhousie University Dr. George Zogopoulos, MD, Ph.D., FRCS(C), FACS Associate Professor, Surgery and Oncology, McGill University; Hepatopancreatobiliary and Transplant Surgeon, The McGill University Health Centre (MUHC) Dr. Steven Gallinger, MD, MSc, FRCSC Hepatobiliary/Pancreatic Surgical Oncologist, Princess Margaret Cancer Centre; Professor of Surgery, University of Toronto; Co-Lead, McCain Centre for Pancreas Cancer
------------------------	---	--

		Dr. Patricia Tang, MD, FRCPC Medical Oncologist, Arthur J.E. Child Comprehensive Cancer Centre; Clinical Associate Professor, University of Calgary <i>Additional panelists yet to be confirmed</i>
1:00 p.m. – 1:45 p.m.	Break Virtual Breakout Room (1:00 p.m. – 1:30 p.m.)	
1:45 p.m. – 3:15 p.m.	Navigating Cancer in the Age of Artificial Intelligence: Opportunities, Risks, and Responsible Use Artificial intelligence (AI) is becoming an increasingly common part of the cancer journey, with patients increasingly using AI-powered tools to better understand their cancer and navigate an increasingly complex healthcare system. While these technologies offer new opportunities to improve access to information and support informed decision-making, they also raise important questions regarding accuracy, misinformation, privacy, bias, and overreliance. Drawing on the experiences of patient support organizations from across Canada, this roundtable will explore how AI is influencing the patient experience and the types of questions, opportunities, and challenges organizations are hearing directly from the communities they serve. Panelists will discuss how patient organizations can help support safe, informed, and responsible use of AI while maintaining trust in evidence-based cancer care. Experts will explore: - Emerging patterns in AI use among younger people affected by cancer and their implications for patient care - Key considerations for ensuring the safe, ethical, and responsible use of AI in cancer care - The role of patient organizations in informing future guidance, education, and advocacy related to AI	<u>Moderator</u> Dr. Isabel Preeshagul, DO, MBS Medical Oncologist; Associate Attending Physician, Memorial Sloan Kettering Cancer Center <u>Patient Group Roundtable</u> Himanshi Singhvi National Patient Support Program Manager, Colorectal Cancer Resource & Action Network Dani Taylor, MSW Manager of Programs, Young Adult Cancer Canada; Stage III Colorectal Cancer (Lynch Positive) Survivor; Patient Advocate Bukun Adegbembo Director of Operations, Canadian Breast Cancer Network Erin Ranger Patient Support Manager, Craig’s Cause Pancreatic Cancer Society <i>Additional panelists yet to be confirmed</i>

3:15 p.m. – 3:30 p.m.	Break	
3:30 p.m. – 3:45 p.m.	Industry Highlight: Innovation in Drug Administration Innovation in drug administration is creating new possibilities for how established cancer therapies can be delivered. This industry presentation will explore what it takes to develop a subcutaneous option for a therapy traditionally delivered intravenously. It will look at the work behind this innovation, from early development through to clinical use, and introduce key differences in how intravenous and subcutaneous treatments are administered. The session will set the foundation for a deeper discussion of subcutaneous treatment in the panel that follows. The presentation will address: • How innovation in drug administration can create new ways to deliver established therapies • The steps involved in moving a new route of administration from development into clinical practice • Key differences between intravenous and subcutaneous administration in practice	<u>Industry Presentation: Merck Canada</u> TBD <i>Presenter yet to be confirmed</i>
3:45 p.m. – 4:45 p.m.	Cancer Care Delivery Through Subcutaneous Treatment How cancer treatment is delivered can have a significant impact on both the patient experience and the capacity of healthcare systems to provide timely care. Subcutaneous formulations are changing how certain cancer treatments, including immunotherapies, can be administered, offering an alternative to traditional intravenous delivery. With substantially shorter administration times, subcutaneous treatment can reduce the time patients spend receiving therapy in cancer centres. This session will examine the role of subcutaneous treatment in cancer care delivery, consider how the shift from intravenous to subcutaneous administration may influence the patient experience and how care is delivered across cancer systems. For younger adults, reducing the time and burden associated with treatment may provide greater flexibility in balancing cancer care with work, family, and life beyond treatment. The discussion will also consider the potential for subcutaneous treatment to support healthcare system capacity and more flexible models of care, alongside the clinical and system-level considerations that will shape its integration into cancer care.	<u>Moderator</u> TBD <u>Patient Perspective</u> TBD <u>Panelists</u> Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A. President & CEO, CCRAN Jasmine MacGowan Executive Director, Save Your Skin Foundation & Ocumel Canada Dr. Lynne Nakashima, BSc(Pharm), PharmD, RPh, FCAPhO, FISOPP Senior Director, Provincial Pharmacy, BC Cancer; Clinical

	Key areas of discussion will include: • Clinical evidence and considerations informing the use of subcutaneous versus intravenous treatment • The role of patient preference and shared decision-making when different treatment delivery options are available • Health-system conditions needed to support appropriate and equitable access to subcutaneous treatment	Professor, Faculty of Pharmaceutical Sciences, University of British Columbia <i>Additional panelists yet to be confirmed</i>
4:45 p.m. – 5:15 p.m.	Session Pending Confirmation	
5:15 p.m. – 5:30 p.m.	Day 2 Closing Remarks and Symposium Adjournment.	Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A. President & CEO, CCRAN